Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Oak Thistle LLC

Oak Thistle LLC grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 59.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,600 shares of the medical equipment provider's stock after buying an additional 10,985 shares during the period. Oak Thistle LLC's holdings in Hologic were worth $1,828,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. KLP Kapitalforvaltning AS boosted its stake in shares of Hologic by 0.4% during the 1st quarter. KLP Kapitalforvaltning AS now owns 276,922 shares of the medical equipment provider's stock worth $17,105,000 after purchasing an additional 1,000 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Hologic during the 1st quarter worth about $42,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Hologic by 14.5% during the 1st quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 448,890 shares of the medical equipment provider's stock worth $27,728,000 after purchasing an additional 56,757 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of Hologic during the 1st quarter worth about $2,299,000. Finally, Wealth Alliance LLC boosted its stake in shares of Hologic by 6.4% during the 1st quarter. Wealth Alliance LLC now owns 5,656 shares of the medical equipment provider's stock worth $349,000 after purchasing an additional 341 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 0.6%

Shares of HOLX traded up $0.40 during mid-day trading on Friday, hitting $66.50. The company's stock had a trading volume of 1,116,538 shares, compared to its average volume of 1,795,352. The company's 50-day moving average is $63.33 and its 200-day moving average is $63.00. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The firm has a market capitalization of $14.82 billion, a price-to-earnings ratio of 28.06, a PEG ratio of 2.42 and a beta of 0.55. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. Hologic's revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.03 EPS. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of Hologic stock in a transaction that occurred on Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director directly owned 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 1.88% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on HOLX shares. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Raymond James Financial reissued an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Mizuho boosted their price objective on shares of Hologic from $65.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Finally, Evercore ISI boosted their price objective on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Hologic currently has an average rating of "Hold" and an average target price of $77.33.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.